Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Sarcosine vs. placebo in subjects at risk for developing schizophrenia:efficacy and safety.
Sarcosine is superior to placebo in the treatment of positive, negative, and cognitive (disorganized) symptoms. Safety assessed with UKU scale, vital signs measurements and laboratory parameters (SMA-20, CBC, UA)
Sarcosine vs. placebo in the treatment of neurocognitive dysfunction
To assess the efficacy of sarcosine in delay/prevention of illness progression.
12 Years to 45 Years (Child, Adult)
Heresco 3 CTIL 101-06
January 13, 2006
June 4, 2014
Ezrath Nashim - Herzog Memorial Hospital Jerusalem, Israel
Department of Psychiatry, Hadassah Hospital and Community Clinics Jerusalem, Israel
† Study has passed its completion date and status has not been verified in more than two years.